Needle-Free Injection Systems Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)
Get a Comprehensive Overview of the Needle-Free Injection Systems Market Report Prepared by P&S Intelligence, Segmented by Product (Prefilled, Fillable), Type (Liquid-Based, Projectile/Depot-Based, Powder-Based), Technology (Jet-Based, Spring-Based, Laser-Powered), Usability (Reusable, Disposable), Application (Vaccine Delivery, Insulin Delivery, Pain Management), Delivery Site (Subcutaneous, Intramuscular, Intradermal), End User (Hospitals & Clinics, Home-Care Settings, Research Laboratories), and Geographic Regions. This Report Provides Insights From 2019 to 2032
Explore the market potential with our data-driven report
Needle-Free Injection Systems Market Future Prospects
The global needle-free injection systems market is estimated to value USD 182.3 million in 2024, and it is projected to expand at a CAGR of 14.8%% during 2025–2032, to generate USD 543.4 million by 2032.
This can be ascribed to the augmenting cases of chronic diseases; the worldwide growing diabetic population, which produces a high demand for self-injection devices; an increasing prevalence of needlestick injuries; and fear of needles among people. As a consequence, there is an increasing requirement for advanced and safer methods of disease management and treatment, such as needle-free injection systems.
The geriatric population is more prone to needing frequent medication and vaccination. However, most of the aged population has higher pain sensitivity and may face problems with the traditional injection procedures through needles. Needle-free injection systems cause less pain and are, therefore, a more-accessible option. Older adults are prone to chronic diseases, which require a prolonged treatment, which could easily be managed with needle-free approaches.
The emergence of innovative healthcare technologies with the increasing funding in the research and development of needle-free delivery systems and governmental initiatives for the same contribute to the market growth. For instance, laser-based systems have the ability to precisely manage drug delivery quantity and depth, and its high adoption rates in aesthetic skin treatment techniques.
Essentially, the surge in needlestick injuries is projected to boost the demand for needle-free injectors as they reduce these risks. They also restrict the transmission of infectious diseases by preventing cross-contamination. Tainted needles can cause contagious diseases, such as HIV/AIDS, hepatitis B, and hepatitis C. As per the NIH, over 5% of the global HIV cases are a result of tainted needles.
Needle-Free Injection Systems Market Trends and Growth Drivers
Technological Advancements are Major Trends
The technological advancements in needle-free injection systems have revolutionized vaccine and therapeutic drug delivery by offering a safer, more-efficient alternative to traditional needles.
As per an article by the World Economic Forum, the Bubble Gun technology could prove to be a future breakthrough in needle-free injection systems. Developed by researchers from the Netherlands, the system administers injections without the use of needles via a system called laser-induced confined cavitation. The technology involves rapidly heating a liquid within a glass container using a laser, creating a high-velocity bubble and allowing the delivery of the liquid substance through the skin at over 100 km/h.
This process is more convenient, safer, and easily tolerable, with no sore points and no puncture wounds. This technology is expected to boost vaccination rates considerably and decrease trypanophobia (fear of needles) and risk of contamination.
Moreover, PharmaJet's products, such as Tropis and Stratis, work by using spring-powered mechanisms, which force a narrow stream of fluid into the skin within a fraction of a second. These methods render needles unnecessary, thus reducing the risk of needlestick injuries and infections. This way, the problems of disposing of single-use syringes diminishes, along with associated expenses for waste management in healthcare facilities.
Additionally, these systems have demonstrated superior clinical outcomes, particularly in vaccine delivery. They enable dose-sparing strategies, reducing the cost of vaccines by up to 50%, which is beneficial in resource-limited locations. The systems are also user-friendly, requiring minimal training, and are not dependent on external power sources, which makes them amenable to being used in remote or under-resourced areas.
Increasing Demand for Self-Injection Systems Drives the Market
With needle-free injections, patients with chronic conditions who self-inject drugs have more control over their treatment schedules, becoming more independent and freer in their social, personal, and work lives.
Self-injections also provide psychological advantages over professional administration, such as increased self-esteem and reduced anxieties associated with clinical visits.
The elimination of the need for frequent injections at a clinic or hospital ultimately keeps costs down for both patients and medical systems. Thus, the need for cost-effectiveness is a primary driver of the needle-free injection systems market growth.
Self-injection technologies also reduce the dose of drugs, hence improving patient compliance, especially with elderly patients.
Drugs that have to be injected for immediate effect raise the risk of needlestick injuries. To curb this, pharmaceutical companies are developing advanced, user-friendly, needle-free injectors and self-administrable drug–device combinations.
Jet injectors have further enhanced the convenience of administering drugs and improved effectiveness, which, subsequently, has led to better patient adherence, while reducing hospital stays and healthcare costs.
The persistent rise in the incidence of chronic diseases increases the need for more-scalable self-injection technologies with improved convenience for the patient.
As per the International Diabetes Federation, the number of people with diabetes around the world is expected to rise to 783 million by 2040 from 536 million in 2021.
Since most diabetics inject insulin multiple times a day, the surging incidence of this disease is a direct needle-free injection systems market growth driver.
High Cost Associated with Needle-Free Injections System Hampers Market Growth
The high manufacturing cost poses an obstacle to small and medium enterprises that have limited budgets. Their high production cost is due to the complex designs needed, which, in turn, increases infrastructure and labor costs. High initial investments result in high unit costs and a lower patient acceptance of these devices. The starter kits of a needle-free injection system are available for USD 165 to 300; however, 1,000 conventional needled syringes cost between USD 5 and 15. Therefore, affordability is one huge challenge that needs to be overcome for needle-free devices to find widespread acceptance.
Needle-Free Injection Systems Market Analysis
Product Analysis
Fillable is the larger category in this market with an estimated value of USD 110 million in 2024. Fillable offers for individualized dosing and flexibility to use a formulation of choice, popularizing across the healthcare provider and patient spaces. It can contribute to the higher demand for personalized medicine and the need for adaptable solutions.
Fillable systems enable the tailoring of doses as per patient needs and this further facilitates patient satisfaction. Additionally, improvements in technology are driving progress in the design and use of fillable injectors, which has further increased their acceptance in clinical and home care settings.
Prefilled is fastest-growing category in this market, primarily because most of these prefilled syringes are automated, reducing the risk of physical handling and ensuring safer use.
Moreover, the U.S. is the largest revenue contributor to the prefilled needle-free injectors market, due to the large diabetic and chronic disease patient base in the country. Furthermore, these advanced systems help patients to reduce the risk of contamination or human-caused dosing errors.
The products evaluated here are:
Prefilled (Faster-Growing Category)
Fillable (Larger Category)
Type Analysis
The liquid-based category is estimated to have the largest share in 2024.
Liquid-based injectors are widely used for delivering vaccines and biologics and popularized by the ease of use and effectiveness.
They ensure delivery of the medication rapidly and effectively, while allowing for consistent dosing and reliable absorption of drugs.
The powder-based category will have the highest CAGR, of 15%, over the forecast period.
Powder-based injectors with dry formulations, which can be reconstituted at the time of delivery, are becoming popular as they enable stability, easy storage, and long shelf life of the drug.
In addition, powder-based injectors significantly lower the risks of contamination and offer flexible dosing.
The types analyzed here are:
Liquid-Based (Largest Category)
Projectile/Depot-Based
Powder-Based (Fastest-Growing Category)
Technology Analysis
The jet-based technology contributes the largest revenue to the needle-free injection systems market, of 70%, and it is also the fastest-growing category. This can be attributed to its benefits, including less time being spent on preparing and administering the medication, fewer needlestick injuries, convenience in usage and aesthetics, and a lower chance of disease spreading.
The technology evaluated in this report are:
Jet-Based (Largest and Fastest-Growing Category)
Spring-Based
Laser-Powered
Usability Analysis
Reusable devices will account for higher revenue in the market in 2032.
This is primarily ascribed to their ability to be refilled for multiple administrations. Consequently, they are less expensive for patients and healthcare providers in the long run.
This utility appeals to individuals managing chronic conditions, especially diabetes, as they can save on the ongoing expenses associated with disposable devices.
Moreover, the rising adoption of sustainable practices in healthcare is driving demand for reusable devices because they cause less medical waste compared to disposables.
The demand for disposable needle-free injectors is expected to grow faster in the coming years.
This is because their disposable feature minimizes the risk of cross-contamination, thus ensuring compliance with safety protocols. They also reduce the need for sterilization, which would propel their adoption in clinical and homecare settings.
The segment is bifurcated as below:
Reusable (Larger Category)
Disposable (Faster-Growing Category)
Application Analysis
Vaccine delivery is the largest category in the market on account of the government drives for vaccination, especially in light of the pandemic. Additionally, all children must be immunized at six months, and since most infants and small kids are afraid of needles, these systems are ideal to uphold patient compliance. Additionally, the ease of administration with needle-free systems makes them suitable for mass vaccination programs; they can be applied rapidly and efficiently in a variety of settings, from clinics to field operations.
As per the World Health Organization (WHO) 84% of the infants, numbering 108 million, received all three DPT trivalent vaccine doses in 2023. Similarly, compared to 20% in 2022, 27% of the girls worldwide received their first dose of human papillomavirus vaccine in 2023. The WHO also says that 14.5 million children did not receive any vaccine in 2023, reflecting a huge unmet demand for syringes and potential opportunities for needle-free injection systems for vaccination.
The insulin delivery category is the most rapidly growing in the market. This growth is driven by the growing incidence of diabetes around the world and an increase in the demand for convenient and patient-friendly drug delivery options. The administration of accurate dosage without needles reduces the fear and discomfort associated with injections, especially in the elderly and those with trypanophobia.
Moreover, as per an article in The Lancet, from 355,900 in 2021, the number of new type 1 diabetes cases in children is expected to rise to 476,700 by 2050. Since almost all children are afraid or uncomfortable with needles, needle-free injection systems for insulin delivery could continue to witness a rise in demand.
The applications evaluated here are:
Vaccine Delivery (Largest Category)
Insulin Delivery (Fastest-Growing Category)
Pain Management
Others
Delivery Site Analysis
The subcutaneous category accounts for the largest revenue share in the market, of 50%, in 2024, and it is expected to maintain its position during the forecast period as well.
There are various applications of subcutaneous injections, including biologics, insulin, and vaccines. Subcutaneous injections are relatively convenient and, thus, favored; they can also be self-administered by patients in a less-invasive manner.
Subcutaneous delivery offers the right absorption rate for many drugs, and hence, wide usage is seen for chronic disease management and preventive purposes.
Intradermal is the fastest-growing category during the forecast period.
The growth in the usage of intradermal injections for vaccine delivery, allergy testing, and therapeutic interventions drives the growth of this category.
Intradermal delivery enables the exact administration of a small volume of medication directly to the dermal layer, thereby boosting the immune response to vaccines and improving the efficacy of some therapies.
The delivery sites analyzed in this report are:
Subcutaneous (Largest Category)
Intramuscular
Intradermal (Fastest-Growing Category)
End User Analysis
Hospitals and clinics are the largest end user of needle-free injection devices and the category accounts for the highest market share. This is attributed to the technical advancements, rise in demand for vaccinations, and increase in usage of medication delivery systems due to the high-patient traffic in hospitals and clinics.
The fastest growth will be observed in the home care settings category during the forecast period, with 15.5% CAGR, due to the rapid surge in the number of diabetic patients. Homecare settings assist patients in managing their treatment conveniently and themselves, which leads to an improvement in adherence and quality of life. Needle-free injectors are highly attractive since they minimize the distress and fear associated with injections, thereby increasing the viability of self-administration for patients.
The end users analyzed here are:
Hospitals & Clinics (Largest Category)
Home-Care Settings (Fastest-Growing Category)
Research Laboratories
Others
Drive strategic growth with comprehensive market analysis
Regional Analysis
The North American needle-free injection systems market is the largest, with an estimated revenue of USD 70 million in 2024, and it is expected to lead the market in the future as well. This is due to the presence of well-developed healthcare infrastructure, a high level of patient awareness, an increase in cases of chronic diseases, and high R&D spending on needle-free injection technologies.
The government initiatives and programs aimed at stimulating the development of innovative healthcare solutions and increasing medication access to the masses play a significant role in the growth of the market. As the emphasis of healthcare systems is on providing better-quality care at minimal costs, the routine use of needle-free technologies has become common, thus leading to an efficient and productive healthcare environment.
The Asia-Pacific market will register the fastest growth during the forecast period, with a CAGR of 16%. This can be ascribed to the rise in disposable income and the increase in public healthcare expenditure in developing economies like China and India. The surging population presents a vast potential patient base for healthcare services.
Additionally, a substantial increase in healthcare expenditure for the expansion of the healthcare industry drives the market. Such initiatives are targeted at widening the access to medical technologies and promoting preventive healthcare. According to the Press Information Bureau, government spending on healthcare in India rose from INR 5,16,427 crore in FY 21–22 to INR 5,48,855 crore in FY 22–23.
The geographical breakdown analyzed here is as follows:
The needle-free injection systems market is consolidated, owing to the presence of a few dominant players, who have significant technological expertise and strong logistics networks.
The leading companies invest heavily in research and development to create innovative and efficient needle-free injection systems. These advancements often result in better product offerings that can outperform competitors’ and cater to the evolving healthcare need, thus, ensuring their continued market dominance. Additionally, major pharmaceutical, biopharmaceutical, and medical device firms usually hold several patents for their technologies and processes, hence deterring the entry of new players.
Navigating the complex technical landscape and ensuring compliance with the regulations on medical equipment and devices need specialized resources and expertise. Companies that have been operational for decades are better positioned to meet these regulatory requirements, making it difficult for newcomers to compete effectively.
Key Providers of Needle-Free Injection Systems:
Portal Instruments Inc.
Inovio Pharmaceuticals Inc.
National Medical Products Administration
PenJet Corporation
PharmaJet Inc.
NuGen Medical Devices
Medical International Technology Inc.
Crossject SA
Ferring B.V.
Needle-Free Injection Systems Market News
In September 2024, PharmaJet Inc. entered into a strategic partnership with Scancell to develop and commercialize a needle-free DNA vaccine for advanced melanoma, using its Stratis Intramuscular Needle-free System.
In June 2024, PharmaJet's Tropis intradermal needle-free system was selected for a WHO-led polio immunization campaign in Somalia, created to reach over 170,000 children across four districts. The campaign’s target is to achieve 95% coverage and diminish the immunity gap against type 2 poliovirus.
Frequently Asked Questions About This Report
What is the projected revenue of the needle-free injection systems market in 2032?+
The 2032 revenue of the market for needle-free injection systems is estimated to reach USD 543.4 million.
Which is the largest end user in the needle-free injection systems industry?+
Hospitals and clinics are the largest end users in the needle-free injection systems industry.
Which factor drives the growth of the needle-free injection systems market?+
Growing demand for insulins and vaccines propels the market for needle-free injection systems.
What is the needle-free injection systems industry nature?+
The needle-free injection systems industry is consolidated.
Which is the fastest-growing needle-free injection systems market by region?+
APAC is the highest CAGR in the market for needle-free injection systems.
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws